Wegovy for Teenagers: Patient + Parent Guide (Evidence Review)

The honest answer: Wegovy is FDA-approved for adolescents 12 and older with obesity (BMI at or above the 95th percentile for age and sex) — approved December 2022 based on the STEP TEENS trial showing roughly 16% mean BMI reduction at 68 weeks. Saxenda (liraglutide 3 mg) is also FDA-approved for adolescents 12+. Zepbound is NOT approved for adolescents as of 2026. The first-line intervention per the American Academy of Pediatrics is structured lifestyle therapy; pharmacotherapy is added when lifestyle alone is insufficient. This guide is for parents and teenagers weighing the decision. It walks through what the FDA has actually approved, what the STEP TEENS trial^[1] showed (and what it did not), the BMI-percentile criteria your pediatrician will use, the adolescent-specific safety considerations — including the FDA-label mood and suicidality monitoring guidance that is especially relevant in this age group — cost and insurance reality, and how to have the conversation with your pediatrician. For the deeper clinical-trial deep-dive, see our companion article on what STEP TEENS showed about semaglutide for adolescents.

What is FDA-approved for teenagers in 2026

As of May 2026, three FDA-approved chronic weight-management prescription medications carry indications that include adolescents 12 and older. The picture is narrower than the adult landscape:

The clinical conversation parents most commonly walk into is about Wegovy or Saxenda. Wegovy is the newer, more effective, weekly option and produces roughly the same magnitude of effect in adolescents that it does in adults; Saxenda is older, requires a daily injection, and produces a smaller weight-loss effect. Qsymia is the only oral option and is prescribed less often. For the broader landscape of FDA-approved GLP-1 and combination weight-loss medications across all ages, see our full GLP-1 medication reference.

STEP TEENS trial: what the data showed

STEP TEENS is the trial that made Wegovy available to adolescents. It was a phase 3, double-blind, randomized, placebo-controlled trial of 201 adolescents aged 12 to less than 18, conducted across the US, Europe, Mexico, and the Russian Federation, and published in the New England Journal of Medicine on November 2, 2022^[1]. Participants had obesity (BMI at or above the 95th percentile for age and sex) or were overweight (BMI at or above the 85th percentile) with at least one weight-related comorbidity. Randomization was 2:1 to weekly semaglutide 2.4 mg subcutaneous injection or placebo, both layered on top of intensive behavioral counseling on diet and physical activity. Total treatment duration was 68 weeks.

The primary result was unusually large for a pediatric weight trial:

Roughly 73% of treated adolescents achieved at least 5% BMI reduction (vs 18% on placebo), and the absolute weight difference between arms exceeded 15 kg on average^[1]. The adolescent placebo arm gained a small amount of BMI on average — the natural history of untreated adolescent obesity is gradual progression, not stability — which makes the treatment effect even larger than the semaglutide-arm number alone suggests. For comparison, adolescent weight-loss trials before STEP TEENS typically reported response rates in the 10-25% range.

Adverse events in STEP TEENS were predominantly gastrointestinal (nausea, vomiting, diarrhea), predominantly mild to moderate, and concentrated during the dose-escalation weeks^[1]. Roughly 4% of adolescents in the semaglutide arm developed cholelithiasis (gallstones), vs 0% on placebo — a higher rate than was seen in the adult STEP-1 trial. The Wegovy FDA prescribing information specifically notes that cholelithiasis, cholecystitis, hypotension, rash, and urticaria were more commonly reported in adolescents than in adults treated with semaglutide^[5]. Pancreatitis occurred in neither arm during the 68-week treatment period.

BMI percentile eligibility (95th percentile for age + sex)

The pediatric definition of obesity differs from the adult definition because adolescents are still growing. Instead of the adult threshold (BMI ≥ 30 kg/m²), pediatric obesity is defined by BMI at or above the 95th percentile for age and sex on the CDC growth charts^[7]. The Wegovy adolescent indication mirrors this threshold: a 14-year-old qualifies if his or her BMI falls at or above the 95th percentile for 14-year-olds of the same sex on the CDC growth chart, regardless of the absolute BMI number.

A few practical numbers to anchor on:

• A 14-year-old boy at the 95th BMI percentile sits at roughly BMI 25-27 (the exact threshold depends on the month of age).
• A 16-year-old girl at the 95th percentile sits at roughly BMI 28-30.
• Severe pediatric obesity (Class II / Class III) is defined as BMI ≥ 120% of the 95th percentile, and the AAP recommends adolescents at this level be evaluated for metabolic and bariatric surgery in addition to pharmacotherapy^[3].

For an interactive estimate using your teen's height, weight, age, and sex, see our BMI calculator. The tool is a starting point for the conversation, not a diagnostic substitute — the formal pediatric BMI-percentile determination should be done in the pediatrician's office using a recent measured height and weight plotted on the CDC growth chart.

Safety considerations specific to adolescents

The Wegovy safety profile in adolescents is broadly similar to adults — predominantly GI tolerability, predominantly mild to moderate, predominantly resolving with continued use^[1]. Several considerations warrant extra attention in the adolescent population:

• Gallstones (cholelithiasis). The 4% rate in the semaglutide arm of STEP TEENS, vs 0% on placebo, is notably higher than what adult STEP trials reported. Rapid weight loss is a known risk factor for gallstone formation, and the adolescent weight-loss trajectory can be steeper than in adults. Symptoms warranting an urgent pediatrician call: right upper-quadrant abdominal pain (especially after fatty meals), nausea, vomiting, fever, or yellowing of the skin or eyes.
• Pancreatitis. No cases occurred in STEP TEENS during the 68-week treatment period^[1], but the Wegovy FDA label still carries the class warning for acute pancreatitis^[5]. Severe, persistent abdominal pain — especially radiating to the back — warrants stopping the medication and an immediate medical evaluation.
• Thyroid C-cell tumors. The Wegovy label carries a boxed warning for thyroid C-cell tumors based on rodent carcinogenicity studies^[5]. A personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) is a contraindication. Ask your pediatrician about your family history before starting.
• Rash and urticaria. Reported more commonly in adolescents than in adults per the FDA label^[5]. New skin reactions warrant a prescriber call.
• Dehydration and kidney injury. Persistent vomiting or diarrhea can cause volume depletion. Adolescents on Wegovy should maintain consistent fluid intake, especially during dose-escalation weeks and during sports participation.

Mood + suicidality monitoring — FDA label guidance

This is the safety section that warrants the most attention in the adolescent population. Section 5.2 of the Wegovy prescribing information explicitly addresses suicidal behavior and ideation^[5], noting that the FDA has reviewed post-marketing reports of suicidal thoughts and behaviors in patients treated with weight-management medications including Wegovy. The label states that prescribers should:

• Monitor patients for depression, suicidal thoughts, or unusual changes in behavior — especially when starting therapy and during dose changes.
• Discontinue Wegovy in patients who develop suicidal thoughts or behaviors.
• Avoid Wegovy in patients with a history of suicidal attempts or active suicidal ideation.

The clinical context that makes this section especially relevant for adolescents: adolescent obesity is frequently comorbid with depression and anxiety, baseline rates of adolescent mood disorders are higher than they were a decade ago, and the relationship between rapid weight loss and mental health in this age group is not as well characterized in published trials as it is in adults. STEP TEENS reported no statistically significant mood signal in either direction^[1], but the trial was not powered for mental health endpoints. The practical implication: families and pediatricians should treat ongoing mental health check-ins as a routine part of Wegovy therapy in adolescents, not as an afterthought. For the broader evidence on GLP-1 mood signals across adult and adolescent populations, see our GLP-1 depression and suicidality evidence review.

Growth + puberty considerations

STEP TEENS did not report linear growth (height) outcomes as a primary or secondary endpoint, and the trial duration of 68 weeks is short relative to the adolescent growth window^[1]. There is no published evidence as of 2026 that Wegovy interferes with linear growth or pubertal development, but there is also no multi-year published follow-up dataset confirming the absence of an effect. The honest framing:

• Linear growth. Should be monitored at every pediatrician visit. Plotting height-for-age across visits tells you whether your teen is tracking along their previous growth curve.
• Pubertal staging. Tanner staging is part of routine adolescent care and should not be skipped while on Wegovy. Any deviation from expected progression warrants a conversation about whether to continue therapy.
• Bone density. Rapid weight loss is associated with reduced bone mineral density in any population. In adolescents, who are still building peak bone mass through their late teens and early 20s, this is a more pressing question than in adults. STEP TEENS did not measure bone density directly. A separate ongoing trial is designed to address this question; published results are not yet available.
• Nutritional adequacy. Reduced appetite is the intended mechanism of Wegovy, but adolescents have higher protein, calcium, iron, and micronutrient needs than adults. A registered dietitian visit is a reasonable add-on for any teen starting Wegovy, especially female athletes, vegetarian/vegan teens, and teens with restrictive eating histories.

Cost + insurance for pediatric Wegovy prescribing

Cost is, for most families, the largest practical barrier to Wegovy in adolescents. The retail (cash) price of Wegovy is roughly $1,300-$1,500 per month for the maintenance 2.4 mg dose. Novo Nordisk's direct-pay channel (NovoCare) offers a lower cash price for self-pay patients, and the manufacturer savings card can reduce costs for some commercially insured patients.

Insurance coverage for pediatric Wegovy is plan-specific and often more restrictive than for adults:

• Commercial insurance. Many large-employer plans cover Wegovy for adolescents who meet the FDA criteria, subject to prior authorization. The prior-auth documentation typically requires the pediatrician to attest to the BMI percentile, document prior intensive lifestyle intervention, and certify the adolescent meets the FDA-approved age and indication. Step therapy (requiring a prior trial of a cheaper medication first) is uncommon for the adolescent indication because the alternatives are limited.
• Medicaid. State Medicaid coverage of GLP-1 medications for weight management is uneven and changes frequently. Several states cover Wegovy for adolescents who meet the FDA criteria; many do not. Coverage for the underlying diagnosis (severe pediatric obesity) is more consistent than for the medication. Call the state Medicaid help line or your pediatrician's prior-auth team for the current state of coverage.
• Manufacturer savings. The Novo Nordisk patient savings program applies to commercial insurance and self-pay; it is not available for patients covered by government insurance (Medicare, Medicaid, Tricare, VA).

Denials on the first prior-auth submission are common. Appeals are usually successful when the pediatrician's office documents the BMI percentile, the failed-lifestyle-intervention history, and the comorbidity profile (sleep apnea, NAFLD, prediabetes, hypertension, dyslipidemia, polycystic ovary syndrome).

Lifestyle pairing per AAP guidance

The American Academy of Pediatrics published its 2023 Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity^[3] in January 2023 — the first AAP guideline on pediatric obesity in 15 years. The guideline lays out a tiered approach:

1. Intensive health behavior and lifestyle treatment (IHBLT) is the first-line intervention for all adolescents with obesity. The AAP defines IHBLT as structured behavioral counseling delivered face-to-face, typically 26 or more hours of contact over 3-12 months, covering nutrition, physical activity, and behavior change. IHBLT is recommended for all adolescents with obesity, including those who go on to pharmacotherapy or surgery.
2. Pharmacotherapy (including Wegovy and Saxenda) is recommended for adolescents 12 and older with obesity as an adjunct to IHBLT, based on the medication's FDA-approved indication and the adolescent's individual risk/benefit profile^[3].
3. Metabolic and bariatric surgery should be evaluated for adolescents 13 and older with severe obesity (BMI ≥ 120% of the 95th percentile or BMI ≥ 35 kg/m² with comorbidities)^[3].

The AAP's explicit shift away from a “watch and wait” approach was the most newsworthy element of the 2023 guideline. The committee's reasoning: childhood obesity is a chronic disease with high lifetime cardiometabolic and psychosocial morbidity, and delaying evidence-based treatment does not improve outcomes. Wegovy works best when paired with the IHBLT components — nutritional counseling, structured physical activity, sleep regularization, and family-based behavioral support — not as a standalone intervention.

When to talk to your pediatrician

A reasonable threshold for raising the Wegovy conversation with your pediatrician:

• Your teen is 12 or older.
• Their BMI is at or above the 95th percentile for age and sex on the most recent pediatrician-office measurement.
• They have attempted structured lifestyle intervention (dietary changes, increased physical activity, behavioral support) for at least 6-12 months without achieving meaningful weight loss, or they have a comorbidity (prediabetes, type 2 diabetes, NAFLD/MASLD, obstructive sleep apnea, hypertension, dyslipidemia, PCOS) that warrants accelerated intervention.
• They (the teen) are willing to participate in the decision-making, accept the weekly injection, and engage with the lifestyle components alongside the medication.

Questions worth bringing to the visit:

• What is my teen's BMI percentile on today's measurement?
• What comorbidities have we documented, and how do they factor into the prior-authorization narrative?
• What is the lifestyle-intervention plan we will document alongside the pharmacotherapy?
• What is the mental health baseline, and how will we monitor mood, anxiety, and disordered-eating signals throughout therapy?
• What is our plan for monitoring growth, puberty, and bone health while on therapy?
• What is our exit plan? If we stop the medication when my teen ages out of pediatric care or loses insurance, what does the regain trajectory look like, and what do we do?

If your current pediatrician does not feel comfortable prescribing GLP-1 therapy for adolescents (a reasonable position — pediatric obesity medicine is a relatively new subspecialty), ask for a referral to a pediatric weight management center, pediatric endocrinology, or pediatric obesity medicine specialist. Our guide to finding a GLP-1 prescriber covers how to identify clinicians who routinely prescribe GLP-1 therapy — the adolescent-specific equivalent is usually a pediatric weight-management clinic affiliated with a children's hospital. For families considering alternatives to Wegovy specifically, our Wegovy alternatives review walks through the broader options. For an honest week-by-week picture of what the first month of therapy actually looks like, see starting Wegovy: what to expect in the first month.

FAQ

See the schema-marked Q&A block below for the structured answers; the long-form discussion above covers the same territory in depth.